Significant Applications in Health Care, Food Quality and Safety and More
SEATTLE, March 19, 2025--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company’s website at www.knowlabs.co.
An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have contact with the liquid but rather detects the change from the outside of a PVC pipe. Second, the change is detected using a Linear Discriminant Analysis model using values from an inverse Fourier transform of the frequency data as its features. We believe this to be the first use of Fourier analysis in contactless pH measurement using radio frequencies."
The impetus for the Know Labs research on pH levels derives from the Company’s historic focus on medical diagnostics with an emphasis on its proof-of-concept work on blood glucose monitoring. At the same time, the Know Labs team explores other applications of its sensor technology. In this case, pH monitoring is important in medical diagnostics, pharmaceutical manufacturing and food quality and safety and more.
Medical Diagnostics
The importance of pH in medical diagnostics cannot be overstated. Accurate pH measurement provides critical insights into the body's physiological state and helps healthcare providers detect, diagnose, and manage a wide range of health conditions. From blood and urine to saliva and cerebrospinal fluid, pH monitoring is an indispensable tool in modern medicine.
Pharmaceutical Manufacturing
The importance of pH in pharmaceutical manufacturing is significant. From drug formulation to production processes, and final product testing, pH control is essential for ensuring the efficacy, stability, and safety of pharmaceutical products. As technology advances, the precision and reliability of pH control will continue to improve, contributing to the development of high-quality pharmaceuticals that meet the needs of patients worldwide.
Food Safety and Food Quality
The pH level, a measure of acidity or alkalinity, is a pivotal factor in determining the quality and safety of food. It influences the taste, texture, color, and shelf-life of food products. Additionally, maintaining appropriate pH levels is essential for preventing the growth of harmful microorganisms, thereby ensuring food safety.
Food safety authorities worldwide recognize the importance of pH in food safety. Regulatory standards often specify pH ranges for different food products to ensure consumer safety. Compliance with these standards helps prevent foodborne illnesses and ensures that food products remain safe for consumption.
"The application of the Know Labs RFDS sensor technology to the medical diagnostics, pharmaceutical manufacturing, and food safety and quality is exactly what we had in mind when we created Know Labs Technology Licensing (KTL) program," said Ron Erickson, CEO and Chairman at Know Labs. "KTL is committed to empowering global corporations, universities, and research institutions to harness RFDS technology securely, efficiently, and at scale across diverse industries and their respective value chains. And by so doing, we plan to bring low-cost, high-quality results to every realm of human activity."
Know Labs, Inc.’s platform technology uses radio frequency dielectric spectroscopy (RFDS) to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market. Other products, developed through KTL, may not require such prior FDA approval.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.
